Here we describe the complete genome of a new ebolavirus, Bombali virus (BOMV) detected in free-tailed bats in Sierra Leone (little free-tailed (Chaerephon pumilus) and Angolan free-tailed (Mops condylurus)). The bats were found roosting inside houses, indicating the potential for human transmission. We show that the viral glycoprotein can mediate entry into human cells. However, further studies are required to investigate whether exposure has actually occurred or if BOMV is pathogenic in humans.
1
. With the exception of RESTV, all have been associated with severe disease in humans. EBOV was the first ebolavirus described and since 1976 more than 25 outbreaks have been recognized 2 . The most significant outbreak occurred in Guinea, Sierra Leone and Liberia in 2013-2016 where an estimated 28,000 humans were infected and 11,325 died 3 . Despite more than 40 years of research and continued outbreaks, the reservoirs of EBOV and the other ebolaviruses remain unknown. Current evidence points to bats [4] [5] [6] [7] [8] [9] , although failure to isolate a virus or recover a complete genome means that no ebolavirus has been conclusively linked to any particular bat species. Therefore, we initiated a survey in Sierra Leone to identify hosts of EBOV as well as any additional filoviruses that might be circulating in wildlife.
Between March and September 2016, 1,278 samples were collected from 535 animals (244 bats, 46 rodents, 240 dogs, 5 cats) from 20 locations in Sierra Leone (Supplementary Figure 1) . Three oral and two rectal swabs from four insectivorous bats were positive using a broadly reactive filovirus 'family-level' consensus PCR (cPCR) assay (4/244, Supplementary Table 1 ). The resulting 680-bp fragment showed 75% nucleotide identity to other known ebolaviruses. Rectal swabs for two of the four positive bats were also positive using a separate ebolavirus 'genus-level' cPCR assay. The resulting 187-bp fragment showed 83% nucleotide identity to known ebolaviruses. All samples collected from dogs, cats and rodents were negative when both assays were used. Given the 2013 Ebola virus disease outbreak, we also screened all samples for EBOV using specific real-time PCR (rtPCR); however, all samples, including those from bats, were negative.
All bats (n = 244) were barcoded to confirm the species (Supplementary Table 1 ). Of the four positive bats, three were identified as little free-tailed bats (Chaerephon pumilus) based on 98% sequence identity in the MT-Cytb gene and 99% in the MT-CO1 gene. The fourth bat was identified as an Angolan free-tailed bat (Mops condylurus) based on 98% identity in the MT-Cytb gene and 99% in the MT-CO1 gene. These bats co-roost and are widely distributed across Western and sub-Saharan Africa (Supplementary Figure 1) . The four positive bats were adult females sampled between the 21 and 28 May 2016 at three different sites within 20 km of each other in the Bombali District (Supplementary Figure 1) . They were sampled inside human dwellings in small villages, where animals (poultry, goats, sheep) and crops (fruit, vegetables, oil trees) were raised for local consumption and sale (Supplementary Table 2) .
Using unbiased high-throughput sequencing, 98% of the genome was recovered from the oral swab of the Angolan free-tailed bat with an average depth of 12× . Using virome capture sequencing (VirCapSeq), 42% of the genome was recovered with an average depth of 5× . Gene walking using PCR and Sanger sequencing was used to obtain a second genome from the rectal swab of a little freetailed bat. The termini for both sequences were then verified using rapid amplification of cDNA ends (RACE) to generate two complete BOMV genomes (GenBank accession numbers: MF319185 and MF319186). The two genomes share 99.1% sequence identity to each other.
Phylogenetic analyses showed that BOMV is sufficiently distinct to represent the prototypic strain of a new species within the
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Ebolavirus genus ( Fig. 1; Supplementary Figure 2) . We suggest the species should be named Bombali ebolavirus to reflect the location of first detection, which is consistent with the naming of other ebolavirus species. Assessment using NCBI's PAirwise Sequence Comparison (PASC) tool supports this new species assignment; it also meets all the criteria for a novel virus species as suggested by Bào et al. 10 ( Supplementary Figure 3) . Overall, the virus showed 55-59% nucleotide identity (64-72% amino acid identity) to other ebolaviruses, though areas of high sequence conservation and high variability were identified throughout the genome (Supplementary Figure 4) . No evidence of recombination was observed. Selection analysis indicated that all genes were undergoing purifying selection; however, several individual residues showed evidence of positive selection (Supplementary Table 3) .
A BOMV-specific rtPCR assay was used to rescreen all samples and to quantify the viral load of positive samples. This assay detected down to 10 genome copies with 91% efficiency and did not crossreact with Marburg virus (genus Marburgvirus, family Filoviridae), Lloviu virus (genus Cuevavirus, family Filoviridae) or other known ebolaviruses (BDBV, EBOV, RESTV, SUDV, TAFV). Viral load in the four positive animals varied from 10,000 to 4 genome copies per μ l. A rectal swab from one additional little free-tailed bat was found to be weakly positive with approximately three genome copies per μ l. Given that little and Angolan free-tailed bats are insectivorous, we considered the possibility that insects or other arthropods could be the source of this virus. However, sequences of arthropod mitochondrial DNA were only obtained from one of the positive samples-the oral swab of the Angolan free-tailed bat. Sequences of two different arthropods were detected: an unidentified butterfly within the Papillionoidea and a hexapod within the Fujientomidae. BOMV load in this specimen was approximately 2,800 genome copies. By comparison, a rectal swab from a little free-tailed bat had an estimated 10,000 genome copies but no arthropod DNA. Therefore, despite previous suggestions that insects may be reservoir hosts or vectors of ebolaviruses 11, 12 , we found no correlation between the presence of insect DNA and BOMV. These data suggest that BOMV was not present merely as a component of the bat diet.
Free-tailed bats have been previously implicated as hosts of ebolaviruses. Both little and Angolan free-tailed bats were shown to survive experimental infection with EBOV (human Kikwit variant 11 ), while Angolan free-tailed bats were suggested as the source of the 2013 Ebola virus disease outbreak in Western Africa 3 . Angolan free-tailed bats were also shown to have antibodies against EBOV or a related virus 5 . The discovery of BOMV further supports their role as hosts of ebolaviruses, although additional surveillance will be required to determine if BOMV is distributed throughout their range and whether these bats sustain BOMV transmission over time (that is, whether they are true reservoirs of BOMV).
Given that BOMV was found in close proximity to humans, we tested whether the BOMV envelope glycoprotein GP1,2 could mediate virus entry into human cells. We generated a recombinant vesicular stomatitis virus (rVSV) encoding the BOMV GP gene (Fig. 2, panel A) , and showed that the rVSV-BOMV GP was infectious in human osteosarcoma (U2OS) cells (Fig. 2, panel B) . These data indicate that BOMV GP1,2 is fully competent to mediate viral 
Fig. 2 | BOMV GP-mediated entry and infection is NPC1
-dependent. a, BOMV GP1,2 is incorporated into rVSV particles. Pelleted rVSV-BOMV GP particles (equivalent to 18,000 infectious units on U2OS cells) were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) followed by immunoblotting with an antiserum specific for ebolavirus GP1 residues 86-97 (EBOV GP1,2 numbering). Western blots were repeated twice, each at three dilutions of rVSV-BOMV GP (Supplementary Figure 5) . b, Infectivity of rVSVs bearing BOMV, EBOV or VSV GPs on wild-type (WT) or NPC1 knockout (KO) U2OS cells complemented with or without human NPC1 cDNA (average ± s.d.; n = 15 from 5 independent experiments for WT and NPC1 KO cDNA cells; n = 6 from two independent experiments for NPC1 KO + cDNA cells; the dotted orange line indicates the limit of detection for the assay). c, GP1 alignment of the known human-infecting ebolaviruses (EBOV, SUDV, RESTV, BDBV, TAFV) and BOMV. Displayed regions pertain to the GP1 interface based on the GP1-human NPC1 crystal structure (PDB: 5F1B). Conserved residues are shown in blue; viral-specific residues in yellow. Squared positions correspond to residues whose side chain heavy atoms are within 5 Å of any heavy atom in the human NPC1 receptor. d, Left panel: atomic representation of the interaction between the human NPC1 (red) and the EBOV GP1 protein (blue) (PDB: 5F1B). Middle panel: close-up view of the interface. Right panel: close-up view of the modelled interface between the human NPC1 crystal structure (red) and the BOMV GP1 atomic model (blue). Displayed viral residues (in yellow) correspond to interfacial positions with different amino acids in the BOMV GP1 protein. Displayed residues on the human NPC1 (in white) correspond to residues with side chain heavy atoms within 5 Å of residues 146 and/or 148 in the EBOV or BOMV GP1.
entry. Entry and infection of rVSV-BOMV GP was also completely dependent on Niemann-Pick C1 protein (NPC1; Fig. 2, panel B) , providing additional evidence that NPC1 is a universal receptor for filoviruses 13, 14 . Sequence analysis showed that BOMV GP1,2 shares 92% of the known NPC1-interacting residues found in other ebolaviruses, with only two unique mutations identified at the binding interface, P146S and A148E (Fig. 2 , panel C) [15] [16] [17] [18] . The corresponding NPC1 residues found within 5 Å of P146S and A148E were conserved between humans and free-tailed bats (both have D502 and V505). Neither of these mutations were predicted to interfere with GP-NPC1 recognition to block binding (Fig. 2, panel D) ; this was supported by our experimental data.
We acknowledge that binding is not the only determinant of host susceptibility; however, it represents the first critical step in spillover. Further, even if BOMV is able to establish a productive infection, it is not known whether the virus is virulent in humans since RESTV can also infect human cells but does not cause disease 19, 20 . Data on pro-inflammatory cytokine expression in human macrophages or the degree to which BOMV antagonizes the human interferon response could help to clarify the pathogenic potential of this virus. Certain key motifs in BOMV viral protein 35 (VP35) (interferon induction) and VP24 (interferon signalling) 19, [21] [22] [23] are more similar to EBOV, while others are more similar to RESTV (Supplementary Figure 4) . Thus, predictions of pathogenicity in humans cannot be made from the sequence alone.
While the pathogenic potential of BOMV is unknown, our data on cell entry suggest that the virus could infect humans. Evidence of ebolavirus-reactive antibodies in humans before the 2013 outbreak 24 suggests that an ebolavirus was already circulating in humans in this area. We suggest that it is unlikely that a virulent pathogen such as EBOV would circulate in humans without causing disease. Given also the cross-reactivity between ebolaviruses (Supplementary  Table 4 , Supplementary Figure 6 ), and that BOMV was discovered in bats inside houses, it is possible that BOMV or some other potentially non-pathogenic ebolavirus has already spilled over. Serosurveys of humans in contact with little and Angolan free-tailed bats would help to confirm whether exposure has occurred.
Our study contributes to a better understanding of the diversity and ecology of ebolaviruses. First, our data provide strong evidence that bats serve as hosts for ebolaviruses and that additional unknown ebolaviruses may exist in wildlife. Identifying these viruses and testing their capacity for human infection would greatly enhance our understanding of 'pre-emergent' viral diversity. Second, it suggests that insectivorous bats play an important role in the ecology of ebolaviruses. To date, surveys have tended to focus on fruit bats. While they seem to be important hosts 4, 5, 25, 26 , we support the previous suggestion by Marí Saéz et al. 2 that future surveillance should be expanded to include insectivorous bats.
Finally, we stress that our study is not meant to create alarm or incite the retaliatory culling of bats. While bats have been implicated as reservoirs for a number of other infectious pathogens, they are also important insectivores, pollinators and seed dispersers. Previous studies have shown that killing or disturbing bats in their natural habitat does not reduce the risk of transmission; rather, it can increase the number of susceptible bats and enhance disease transmission 27 . While BOMV has the potential to infect human cells, there is currently no evidence that the virus causes disease. Nonetheless, local community engagement is ongoing to explain the current state of understanding regarding BOMV.
Methods
Animal sampling.. Oral and rectal swabs, and whole blood when possible, were collected into guanidinium thiocyanate, frozen in liquid nitrogen and stored at − 80 °C until analysis. All animal sampling activities were conducted with permission from The Ministry of Agriculture, Forestry and Food Security and under the Institutional Animal Care and Use Committee at the University of California, Davis (protocol number: 16048). Inactivated samples in guanidinium
Bat host species identification was confirmed by DNA barcoding of the MT-Cytb and MT-CO1 mitochondrial genes 28 . The presence of invertebrate DNA in BOMV-positive samples was examined by PCR for a fragment of the MT-CO1 gene 29 (up to 48 clones sequenced from each).
Viral discovery and sequencing. Total RNA was extracted using Direct-zol RNA columns (Zymo Research) and cDNA prepared using SuperScript III (Invitrogen). Samples were screened using three assays: (1) ) and sequenced on the Miseq platform (Illumina). Contigs and unique singletons were assembled as described previously 32 . A second genome was generated by PCR walking using gene-specific primers. The termini were amplified using RACE, adopting anchor-and virus-specific primers. Host NPC1 sequences were generated by mapping unassembled singletons onto a reference NPC1 gene.
Phylogenetic analyses. Sequences were edited using Geneious (version 9.1.7; https://www.geneious.com/) and aligned with CLUSTALW (https://www.genome. jp/tools-bin/clustalw). Bayesian coalescent phylogenetic analysis was implemented using BEAST (http://beast.community/tree_priors). Nucleotide substitution models were chosen using jModelTest (https://github.com/ddarriba/jmodeltest2) and a Yule process speciation model. Each analysis was run for 1,000,000 generations. Maximum clade credibility trees were generated using the TreeAnnotator program in BEAST and edited using FigTree. Alignments and trees were created separately for each gene and a concatenation was used for the complete genome. Sequences were also analysed using the PASC tool to classify sequences taxonomically 10 . The nucleotide alignment of the ebolavirus genomes was screened for recombination using the seven algorithms in the Recombination Detection Program (version 4.87; http://web.cbio.uct.ac.za/~darren/rdp.html). The ebolavirus nucleotide alignment was analysed for evidence of selection using the SLAC, FEL, MEME and FUBAR algorithms, executed in Datamonkey (http://datamonkey.org/) and with the M7 and M8 codon models in codeml (Phylogenetic Analysis by Maximum Likelihood (PAML) package; http://abacus.gene.ucl.ac.uk/software/paml.html). The codon models in PAML were implemented using both a gene-specific tree for each gene and a species-level tree (the concatenated alignment tree). Model fit was compared using a likelihood ratio test (χ 2 d.f. = 2 ). To visualize the variation in selective pressure across the genome, the empirical Bayes posterior mean ω ± credible interval was plotted for each codon position and colour-coded according to the posterior probability of ω > 1. BOMV GP1,2 interaction with human NPC1. Wild-type (WT) and NPC1 knockout U2OS cells complemented with human NPC1 cDNA were cultured as described previously 34 . Rescue of the rVSVs bearing EBOV GP1,2 and VSV G have also been described previously 35 . The U2OS human carcinoma cell line was obtained from ATCC and authenticated at the source. The U2OS knockout cell line was produced by CRISPR-Cas9 engineering and sequenced to confirm the deletion of the NPC1 allele. All cell lines were routinely tested and were negative for Mycoplasma.
Sequence encoding the full-length BOMV GP1,2 from the Angolan freetailed bat was cloned between MluI and NotI restriction sites into the plasmid VSV vector to replace the VSV G open reading frame 35 . The resulting plasmid was used to rescue the rVSV-BOMV GP virus using the plasmid-based infectious VSV rescue system on 293FT cells as described previously 36, 37 . The 293T human embryonic kidney fibroblast cell line was obtained from ATCC and authenticated at the source. The rescued virus was expanded on Vero cells and the BOMV GP1,2 sequence was verified by rtPCR followed by Sanger sequencing. Incorporation of BOMV GP1,2 into the VSV particles was detected by immunoblotting using a rabbit antiserum specific for ebolavirus GP1 residues 86-97 (EBOV GP numbering) 38, 39 . Monolayers of WT, NPC1 knockout or NPC1 knockout U2OS cells complemented with human NPC1 cDNA U2OS cells were infected with serial log dilutions of rVSVs expressing enhanced green fluorescent protein (eGFP) and bearing the EBOV, BOMV or VSV glycoproteins for 1 h at 37 °C. Ammonium chloride at a final concentration of 20 mM was added at 1 h postinfection to prevent subsequent rounds of infection. Infections were enumerated by counting eGFP-positive cells at 12-14 h post-infection and expressed as infectious units per ml.
Protein structure modelling. A sequence alignment between EBOV GP1,2 and BOMV GP1,2 was carried out with T-coffee (https://www.ebi.ac.uk/Tools/msa/ tcoffee/). Interfacial residues were identified using the crystal structure of the EBOV GP1,2 protein bound to human NPC1 18 . BLAST was used for template search and alignment, while NEST (http://honig.c2b2.columbia.edu/nest/) was used to model the structure of the BOMV GP1,2 40 . A non-redundant set of sequences was assembled, corresponding to the proteins in the NCBI PDB, using a sequence identity cut-off of 1.0 with CD-HIT 43 (http://weizhongli-lab.org/cd-hit/). A single iteration of BLAST was run against this data set and the template and alignment with the lowest e-value was selected (PDB: 5FHC; e-value: 1.4 e
−139
). The interaction of the human NPC1 protein with BOMV GP1,2 was assessed using a structural alignment of the GP1,2 atomic model to the crystallized human NPC1-EBOV GP1,2 protein complex 40 with the SKA program (http://honig.c2b2. columbia.edu/ska).
Peptide enzyme-linked immunosorbent assay (ELISA) assay. We designed and synthesized a series of peptides with increasing specificity for BOMV GP1, including one BOMV peptide with high sequence similarity with the other ebolaviruses (GP-100); one that shares sequence similarity with some, but not all, ebolaviruses (GP-270); and one BOMV peptide that shows no sequence homology with the other ebolaviruses (GP-471, Supplementary Figure 5 ). Our rationale was to demonstrate decreasing cross-reactivity as a function of sequence variation. Peptides with high sequence similarity for EBOV (GP-313) and TAFV (GP-378) were designed to demonstrate specificity of peptides with known sequence homology to other ebolaviruses. ELISA was performed as described by King et al. 43 with slight modifications. We coated plates overnight with each peptide (6 μ g ml
) or recombinant EBOV glycoprotein (0.5 μ g ml
; IBT Bioservices), blocked (1% bovine serum albumin) and used 100 μ l primary rabbit polyclonal antibodies (1:1000 dilution) against EBOV (eENZYME), SUDV (IBT Bioservices), BDBV (Sino Biological) and TAFV (Alpha Diagnostic International Inc.) spiked in 1% dog serum followed by 100 μ l secondary goat anti-rabbit antibodies (ImmunoReagents) (1:2000 dilution) conjugated to an horseradish peroxidase and o-phenylenediamine dihydrochloride substrate. Optical densities were read at 490 nm and signal was considered to be positive when the absorbance was at least three times higher than background.
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Experimental design 1. Sample size
Describe how sample size was determined.
This study represents discovery of a new virus and not surveillance for a known pathogen, and thus sample size could not be determined
Data exclusions
Describe any data exclusions.
No data were excluded
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
Samples were retested to confirm they were positive, tested by multiple assays and sequenced for viral confirmation
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
This does not apply to our study, samples from all animals that were captured and sampled, were tested
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
These are not human samples or part of any clinical trials, thus blinding was not needed Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.) A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials 8. Materials availability Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party.
No restrictions
Antibodies
Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species).
Anti EBOV, TAFV, SUDV, BUDV antibodies were purchased from IBT Bioservices, eEnzyme, Sino Biological Inc., Alpha Diagnostic and R&D systems and validated by the company for use in ELISA platforms. Checkerboard dilutions were performed in our lab to determine the appropriate dilution to use for our ELISA assays and negative controls were included to determine if they cross reacted with non-ebolavirus antigens. Likewise, Rabbit antiserum specific for ebolavirus GP1 was purchased from Santa Cruz Biotechnology and used in immmunoblotting to detect BOMV GP1 VSV particles, used per manufacturer instructions. NPC1 domain C was detected by a horseradish-conjugated anti-Flag antibody (Sigma-Aldrich), using ultra-TMB substrate (Thermo Scientific). This is a standard antibody used to detect Flag tags and is well validated by the company. All appropriate negative controls were used to confirm specific binding.
All commercial vendors provide physical quality control and data sheets for all antibodies. We test all cell lines in culture for mycoplasma on a monthly basis, since contamination can occur sporadically. All incoming cell lines are routinely 'quarantined' until they have been confirmed to be mycoplasma-free.
d. If any of the cell lines used are listed in the database of commonly misidentified cell lines maintained by ICLAC, provide a scientific rationale for their use.
Not applicable
Animals and human research participants
Policy information about studies involving animals; when reporting animal research, follow the ARRIVE guidelines
Description of research animals
Provide all relevant details on animals and/or animal-derived materials used in the study.
Oral and rectal swabs, and whole blood when possible, were humanely collected (capture and release) from live captured animals under permits provided by The Ministry of Agriculture, Forestry and Food Security and under the Institutional Animal Care and Use Committee at the University of California, Davis (protocol number: 16048).
